XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
  AIDS
  Influenza
  MRSA
  Tuberculosis
  Shigella
  HCV
  SARS
  Ebola
  Dengue
  Malaria
  Pertussis
  Mumps
  Prion Diseases
  Small Pox
  Anthrax
  Leishmaniasis
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Tuberculosis Channel
subscribe to Tuberculosis newsletter

Latest Research : Infectious Diseases : Tuberculosis

   DISCUSS   |   EMAIL   |   PRINT
A New Biochemical Target to Attack Resistant Tuberculosis Bacteriae
Mar 16, 2005, 12:55, Reviewed by: Dr.

"We've been able to find at least the beginnings of a class of compounds that we can start working with and that we know is biochemically active against the TB bacteria in culture and in small animals."

 
A worldwide health problem, tuberculosis kills more people than any other bacterial infection. The World Health Organization estimates that two billion people are infected with TB, and that two million people die each year from the disease.

However, due to multi-drug resistance and a protracted medication regimen, it is extremely difficult to treat. Hence, there is still a great deal of interest in developing new anti-tubercular drugs.

Researchers at the University of Pennsylvania School of Medicine have identified a biochemical target that could lead to a new class of antibiotics to fight TB. They report their findings in this week's online edition of the Proceedings of the National Academy of Sciences.

In a proof-of-principle study, Harvey Rubin, MD, PhD, Professor of Medicine, Division of Infectious Diseases, and colleagues were able to stop the bacteria from multiplying by inhibiting the first step in a common biochemical pathway.

This pathway is responsible for making the energy molecules all cells need to survive.

First author Edward Weinstein, an MD/PhD student, Rubin, and colleagues characterized the pathway and showed that an important enzyme in it is a key target for anti-TB agents.

The pathway, explains Rubin, is like a series of links in a chain, with enzymes facilitating reactions along the way. "We discovered that if you inhibit the very first enzyme in the chain, you inhibit everything else downstream and eventually the bacteria die," he explains.

The research group tested phenothiazine, a drug used in the past to treat schizophrenia, in cultures of Mycobacterium tuberculosis, the bacterium that causes TB. They found that phenothiazines killed the bacterium in culture and suppressed its growth in mice with acute TB infection.

While the effect on the growth of TB in mice was small, it suggested that a valid target was identified. The research group went on to show that the enzyme disabled by the phenothiazines is called type II NADH dehydrogenase and is a unique and important antimicrobial target.

"What we have now is a new target in TB," says Rubin. "We've been able to find at least the beginnings of a class of compounds that we can start working with and that we know is biochemically active against the TB bacteria in culture and in small animals."

Is it a new drug for tuberculosis? Not yet, cautions Rubin. It's premature to say that this class of drugs will cure TB, but it does represent the start of basic research towards that, he concludes.

Next steps include more investigations on inhibitors of the NADH biochemical pathway in TB, and the development of high-throughput screens to find better and safer inhibitors of type II NADH dehydrogenase.
 

- This week's online edition of the Proceedings of the National Academy of Sciences
 

University of Pennsylvania School of Medicine

 
Subscribe to Tuberculosis Newsletter
E-mail Address:

 

This work was supported by grants from the National Institutes of Health. Rubin and Weinstein's coauthors are Takahiro Yano, Lin-Sheng Li, David Avarbock, Andrew Avarbock and Douglas Helm from Penn, and Andrew McColm, Ken Duncan, and John T. Lonsdale from GlaxoSmithKline ( Collegeville, PA and Stevenage, UK ). Animal studies were conducted at GlaxoSmithKline. Penn researchers report no conflicts of interest.

PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine ( founded in 1765 as the nation's first medical school ) and the University of Pennsylvania Health System ( created in 1993 as the nation's first integrated academic health system ).

Penn's School of Medicine is ranked #3 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report's most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

The University of Pennsylvania Health System includes three owned hospitals [Hospital of the University of Pennsylvania, which is consistently ranked one of the nation's few "Honor Roll" hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation's first hospital; and Presbyterian Medical Center]; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home care and hospice.

Contact: Karen Kreeger
[email protected]
215-349-5658
University of Pennsylvania Medical Center


Related Tuberculosis News

Emergence of highly drug-resistant tuberculosis strains requires urgent action
Treating populations infected with HIV and latent TB could speed the emergence of drug-resistant TB
Solution to TB epidemic may lie in protective Heme oxygenase 1 protein
Explaining Why People of African Descent Are More Vulnerable to TB
Indian Scientists Identify Key Genes in Tuberculosis Infection
PA-824 holds promise for shortening the TB treatment regimen
DC-SIGN expressing alveolar macrophages are preferentially targeted by M. tuberculosis
Tuberculosis Still a Risk for Patients on Anti-retrovirals
Evolutionary history of tuberculosis is shaped by human migration patterns
TB vaccines will fail in developing countries


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us